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Abstract
A high-throughput screening protocol for evaluating chimeric, self-sufficient P450 biocatalysts and their mutants against a panel of
substrates was developed, leading to the identification of a number of novel biooxidation activities.
Introduction
P450 monooxygenases are a ubiquitous family of enzymes
found in a wide variety of organisms in all domains of life.
These enzymes catalyse oxidation reactions such as hydroxyla-
tion, epoxidation, N- and O-dealkylation and heteroatom oxi-
dation, often with high regio- and stereoselectivity [1], and are
therefore attractive candidates for biocatalyst development.
However, the need for reconstitution of protein redox partners,
the necessary use of expensive NAD(P)H, and the lack of
widely applicable high-throughput screening protocols render
the development of efficient P450 biocatalysts a major chal-
lenge. In recent years, naturally fused P450 enzymes, such as
P450BM-3 [2-7] and P450RhF [8-11], have attracted great
interest, although they represent only a small fraction of the
thousands of naturally occurring P450 enzymes in nature. We
and others have recently reported highly active chimeric P450s
in which the P450 domain of a variety of bacterial enzymes is
fused with the reductase domain of the self-sufficient P450RhF
[12-14].
Given that these chimeric enzymes can function in bacterial
hosts, we proposed that such whole-cell P450 systems would be
amenable to incorporation into a high-throughput screening
protocol in multiwell plates. Figure 1 outlines the design of the
screening platform: E.coli hosts containing a variety of easily
engineered chimeric constructs are incubated with the substrate
under physiological conditions, and the oxidation products
are then analysed by standard analytical methods, such as
GC–MS.
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Figure 1: Oxidation reactions with P450cam-RhFRed mutants.
Scheme 1: Whole cell biotransformation of diphenylmethane to 4-hydroxydiphenylmethane with P450cam(Y96A)-RhFRed.
Results and Discussion
Our previous work showed that the chimera P450cam-RhFRed
allows 100% conversion of camphor to 5-exo-hydroxycamphor
at 3 mM substrate concentration. The substrate specificity of
P450cam can be significantly broadened by specific mutations,
in particular by mutating the tyrosine residue at position 96
(Y96) in combination with other sites such as V247 [15-22].
Exchanging Y96 for an alanine residue allows the oxidation of
unnatural substrates, presumably because it opens up the active
site. S. Flitsch, L.-L Wong and coworkers for example showed
that P450cam (Y96A) was able to hydroxylate diphenyl-
methane to 4-hydroxydiphenylmethane, an activity that was not
observed with the wild-type enzyme [15]. For the present study,
incorporation of the Y96A mutation into our P450cam-RhFRed
fused system made the whole cell biotransformation of diphen-
ylmethane as a substrate possible (4 mL reaction in a
15 mL Falcon tube) with a GC–MS yield of 58% of 4-hydroxy-
diphenylmethane after 48 h (Scheme 1).
In order to improve screening throughput, we investigated the
whole cell biotransformation of diphenylmethane with
P450cam(Y96A)-RhFRed in multiwell plates (24, 48 and 96)
with different reaction volumes (0.5 mL, 1 mL and 2 mL). The
biotransformation carried out in a 48-well plate with a reaction
volume of 1 mL was found to give a similar conversion to the
4 mL reaction in a Falcon tube, and this format was therefore
adopted for subsequent screening of P450cam-RhFRed variants.
In addition to Y96A, mutations Y96F and Y96F/V247A were
incorporated into the P450cam-RhFRed system for investi-
gation, having shown interesting broad substrate ranges in
previous studies with nonfused P450cam.
Initially, the microtitre-plate system was optimised and shown
to give similar yields to our previously reported biotransforma-
tions. The three fused P450cam-RhFRed variants were screened
against a panel of substrates, which were selected on the basis
of the potential application of their oxidation products. For
instance, the terpenes α- and β-ionone and their derivatives have
been widely used for the synthesis of carotenoids or in the
fragrance industry [23-26], and functionalized aliphatic hetero-
cycles are versatile building blocks for further elaboration, e.g.,
by biocatalytic means [27].
The three P450cam-RhFRed mutants were expressed in E. coli
as previously described [12-14] and their presence confirmed by
SDS–PAGE (see Supporting Information File 1). The screening
was carried out at 4 °C in 48-well plates with a reaction volume
of 1 mL (180 mg wet cells/mL phosphate buffer, pH 7.2) and a
substrate concentration of 1 mM. After 24 h and 48 h aliquots
of the reaction mixture were extracted with ethyl acetate and
analysed by GC–MS. In the screening process, previously
undescribed biocatalytic activities were discovered (Table 1).
Thus, the monoterpenes 1, 3 and 5 were hydroxylated by all
three P450cam-RhFRed mutants, with the double mutant
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Table 1: Conversion (% relative peak-area by GC–MS of extracted reaction mixtures), after 24 h, of substrates 1, 3, 5, and, after 48 h, of substrates 7,
11, 13 and 15 with P450cam-RhFRed mutants in 48-well plate biotransformations.
Compounds P450cam-RhFRed mutants
Substrate Products Substrate no. Y96A Y96F Y96F/V247A
1 2
1 >99 >99 >99
3
4
3 94 98 >99
5
6
5 64 50 >99
7
10
7a 12 (8a) — —
7b 48 (8b) 26 (8b) 73 (8b)a
7c 85 (10c)b 16 (8c)34 (10c)
7 (8c)
59 (10c)
31 (10c')
7d n.c.c n.c.c n.c.c
11 12
11a <2 (u)d — —
11b 12 (12b) <2 (u)d 9 (12b)15 (12b')
11c <2 (u)e n.c.c 11 (12c)
11d 88 (12d)f 22 (12d)69 (u)d
18 (12d)
82 (u)d
13 14
13 n.c.c n.c.c 18 (14d)6 (14d')
Beilstein J. Org. Chem. 2011, 7, 1494–1498.
1497
Table 1: Conversion (% relative peak-area by GC–MS of extracted reaction mixtures), after 24 h, of substrates 1, 3, 5, and, after 48 h, of substrates 7,
11, 13 and 15 with P450cam-RhFRed mutants in 48-well plate biotransformations. (continued)
15 16
15 15 (16d)9 (16d')
11 (16d)
10 (16d')
15 (16d)
75 (16d')
aOne other product was detected (8%). bOne other product was detected (10%). cn.c. = no conversion. du = unidentified product. eTwo unidentified
products. fThree other minor products were detected (12%).
Y96F/V247A showing >99% conversion after 24 h (only one
hydroxylated product was detected in the extracts).
Epoxidation of tetrahydropyridine 7a to compound 8a with
P450cam(Y96A)-RhFRed was shown to occur with low conver-
sion (12%) with carboxybenzyl as a protecting group. In order
to optimise the epoxidation reaction further, the N-protection
group was used as another variable in the screening and a
variety of N-protecting groups were installed to generate a set
of tetrahydropyridine derivatives 7. An increase in conversion
(48%) was obtained with tert-butyloxycarbonyl (Boc, com-
pound 7b) instead of benzyloxycarbonyl (Cbz, compound 7a)
protection. In some product mixtures from 7b additional peaks
of hydroxylated compounds were observed, which could corres-
pond to structures 9, but these were not further characterised.
Surprisingly, compound 7c, bearing a protecting group very
similar to Boc, showed mainly hydroxylation of an unactivated
carbon atom of the protecting group. Mutant P450cam(Y96F)-
RhFRed displayed similar results to the Y96A mutant, albeit
with lower conversions. The double mutant P450cam(Y96F/
V247A)-RhFRed turned out to be the most efficient for the
epoxidation of the tetrahydropyridine ring, with substrate 7b
epoxidised to 8b in 73% conversion. Racemic epoxide 8b was
synthesised to confirm the structure of the biotransformation
product and to determine the enantiomeric excess. This was
found to be 18% for the biotransformation reaction with
P450cam(Y96A)-RhFRed, 13% with P450cam(Y96F)-RhFRed
and 15% with P450cam(Y96F/V247A)-RhFRed.
Similar studies were performed with compound 11 in order to
find the combination of P450 mutant and protecting group with
the highest hydroxylation conversion. Low conversions or
mixtures of two products were obtained with compounds 11a,
11b and 11c. Interestingly, when the trifluoroacetyl protecting
group was used (11d) no starting material was detected in the
EtOAc extract of the reaction mixture after 48 h. The mutant
P450cam(Y96A)-RhFRed was shown to convert 11d to one
major hydroxylated product (12d, 88%), with three minor
unidentified products also detected (12%). The other two
mutants also showed high hydroxylation activity with trifluoro-
acetyl-protected 11.
Similar results were obtained with cyclopentylamine and cyclo-
heptylamine derivatives 13 and 15. In the case of compound 13,
only the mutant P450cam(Y96F/V247A) was able to hydroxyl-
ate the ring, and this gave a mixture of two hydroxylated
products. Compound 15 was also shown to give two hydroxyl-
ated products, again with the mutant P450cam(Y96F/V247A)
showing the highest conversions. The regioselectivity of the
hydroxylation of compounds 11, 13 and 15 has not yet been
determined and is currently under investigation.
Conclusion
In summary, we have described a fast screening method that
allows us to find new biocatalysts for oxidation reactions, either
by screening P450 variants or by screening substrate variants
through variation of the protecting group. The combination of
these reaction parameters allowed for the optimisation of a
specific biocatalytic reaction. The biocatalysts are very easy to
generate as bacterial whole-cell systems and the screening
protocol should make this method attractive for the further
discovery and development of new oxidation activity.
Supporting Information
The Supporting Information features the full experimental
procedures, characterisation of the synthesised, previously
unknown compounds, GC–MS traces of the
biotransformation reactions and the MS traces of the
corresponding starting materials.
Supporting Information File 1
Experimental part and GC–MS traces.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-7-173-S1.pdf]
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